Reply

Journal of Allergy and Clinical Immunology

Volumn 133, Issue 3, 2014, Pages 931-932

  Malling, Hans Jørgen ^a   Witten, Marianne ^a   Poulsen, Lars K ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; PLACEBO;

ACTIVE IMMUNIZATION; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INTRALYMPHATIC IMMUNOTHERAPY; LETTER; NOSE PROVOCATION TEST; PEDIATRICS; PRIORITY JOURNAL; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT;

ALLERGENS; HUMANS; IMMUNOTHERAPY; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL;

EID: 84896705471     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.11.037     Document Type: Letter

References (9)

1. T.M. Kündig, P. Johansen, M.F. Bachmann, L.O. Cardell, and G. Senti Intralymphatic immunotherapy: time interval between injections is essential J Allergy Clin Immunol 133 2014 930 931
2. M. Witten, H.J. Malling, L. Blom, B.C. Poulsen, and L.K. Poulsen Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol 132 2013 1248 1252.e5
3. General recommendation on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). 2011. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm. Accessed January 2, 2014.
4. G. Senti, B.M. Prinz Vavricka, I. Erdmann, M.I. Diaz, R. Markus, and S.J. McCormack et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial Proc Natl Acad Sci U S A 105 2008 17908 17912
5. G. Senti, R. Crameri, D. Kuster, P. Johansen, J.M. Martinez-Gomez, and N. Graf et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections J Allergy Clin Immunol 29 2012 1290 1296
6. T. Hylander, L. Latif, U. Petersson-Westin, and L.O. Cardell Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis J Allergy Clin Immunol 131 2013 412 420
7. Commitee for medicinal products for human use (CHMP). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London: European Medicines Agency; 2008.
8. Guidance for Industry. Allergic rhinitis: Clinical development programs for drug products. Draft guidance. U.S. Department of Health and Human Serviced, FDA Food and Drug Adminstration, Center for Drug Evaluation and Research (CDER). Rockville, MD: 2000.
9. G.W. Canonica, C.E. Baena-Cagnani, J. Bousquet, P.J. Bousquet, R.F. Lockey, and H.J. Malling et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce Allergy 62 2007 317 324